Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868140 · ClinicalTrials.gov registry record · NA
Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)
A NA study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT00868140 is a NA study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 51 participants.
The verdict
NCT00868140, a NA study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
Our hypothesis is that hyperinsulinemia increases the renal clearance of D-chiro-inositol (DCI) in women with polycystic ovary syndrome (PCOS) and that this leads to a reduction in circulating insulin-stimulated D-chiro-inositol-containing inositol phosphoglycan (DCI-IPG) release. To assess the effects of a chronic reduction in circulating insulin on DCI metabolism, we propose to reduce circulating insulin in obese women with PCOS by improving insulin sensitivity with the drug pioglitazone. Pioglitazone is a thiazolidinedione that improves peripheral insulin sensitivity, presumably by activation of the peroxisome proliferator-activated receptor gamma (PPARγ) receptor. Administration of pioglitazone to women with PCOS has been shown to improve insulin sensitivity, reduce insulin secretion, and decrease both fasting and post-prandial serum insulin concentrations.
Interventions
- DRUG Placebo
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868140
The ClinicalTrials.gov registry entry for NCT00868140 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00868140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00868140 about?
NCT00868140 is a clinical study titled "Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)". Our hypothesis is that hyperinsulinemia increases the renal clearance of D-chiro-inositol (DCI) in women with polycystic ovary syndrome (PCOS) and that this leads to a reduction in circulating insulin-stimulated D-chiro-inositol-containing inositol phosphoglycan (DCI-IPG) release. To assess the effe...
What is the current status of trial NCT00868140?
This trial is currently terminated. It is a NA study. The enrollment target is 51 participants. The study started on 2009-02. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00868140?
The interventions under investigation include: Placebo (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00868140?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.